Genentech snags a PhII-ready IL-33 asthma/COPD drug from Amgen

John Carroll

has moved to the head of a small group of players in the anti-inflammatory arena, bagging rights to an antibody that scrambles the connection between IL-33 and the ST2 receptor–two biomarkers pegged for their role in a variety of lung ailments– .

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2019 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS